XML 152 R40.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaboration, License and Research Agreements - Additional Information (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Nov. 27, 2023
USD ($)
shares
Nov. 30, 2023
USD ($)
$ / shares
shares
Apr. 30, 2019
USD ($)
Product
Obligation
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Collaboration revenue       $ 10,897 $ 9,560 $ 9,224
Research Collaboration, License Agreement and Securities Purchase Agreement with BMS            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Upfront fees received   $ 100,000        
Collaborative arrangement, nonrefundable cash payment received   60,000        
Sale of stock, consideration received on transaction   40,000        
Cumulative spending cap   40,000        
Collaboration revenue       $ 9,800 0  
Research Collaboration, License Agreement and Securities Purchase Agreement with BMS | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenue, remaining performance obligation, period       7 years    
Research Collaboration, License Agreement and Securities Purchase Agreement with BMS | First Unit Of Accounting            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenue, remaining performance obligation, amount   68,700        
Research Collaboration, License Agreement and Securities Purchase Agreement with BMS | Second Unit Of Accounting            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenue, remaining performance obligation, amount   $ 31,300        
Research Collaboration, License Agreement and Securities Purchase Agreement with BMS | Private Placement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Sale of stock number of shares issued in transaction (in shares) | shares 5,075,304 5,075,304        
Sale of stock, consideration received on transaction $ 40,000 $ 40,000        
Sale of stock, price per share (in dollars per share) | $ / shares   $ 7.8813        
Premium In excess of fair value $ 8,700 $ 8,700        
Research Collaboration, License Agreement and Securities Purchase Agreement with BMS | Maximum            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Development milestone payment eligible to receive   1,350,000        
Commercialization milestone payment eligible to receive   $ 825,000        
Research Collaboration and License Agreement with Eli Lilly            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Upfront fees received     $ 20,000      
Collaboration revenue       $ 1,100 9,500 $ 9,000
License agreement expiry period     10 years      
Number of performance obligation | Obligation     1      
Period for expected performance obligation       5 years    
Collaboration receivables       $ 0 $ 800  
Research Collaboration and License Agreement with Eli Lilly | Maximum            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Development milestone payment eligible to receive     $ 60,000      
Commercialization milestone payment eligible to receive     $ 205,000      
Rights to antibody oligonucleotide conjugates for messengers RNA targets. | Product     6      
Regulatory milestone payment eligible to receive     $ 140,000